Indivior PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IZQVF research report →
Companywww.indivior.com
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex.
- CEO
- Mark Crossley
- IPO
- 2014
- Employees
- 1,000
- HQ
- North Chesterfield, VA, US
Price Chart
Valuation
- Market Cap
- $2.89B
- P/E
- 18.77
- P/S
- 3.63
- P/B
- -32.72
- EV/EBITDA
- 11.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 83.11%
- Op Margin
- 33.31%
- Net Margin
- 19.44%
- ROE
- -142.01%
- ROIC
- 85.68%
Performance & Tape
- 52W High
- $26.50
- 52W Low
- $15.00
- 50D MA
- $18.99
- 200D MA
- $19.42
- Beta
- -0.06
- Avg Volume
- 3.59K
Get TickerSpark's AI analysis on IZQVF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IZQVF Coverage
We haven't published any research on IZQVF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IZQVF Report →